Latest news

Thumbnail image for PHE says uptake of bowel cancer screening too low

PHE says uptake of bowel cancer screening too low

Public Health England is urging all men and women over the age of 60 to get screened for bowel cancer, after fresh data show over 40 percent are not getting tested, “putting thousands unnecessarily at risk of dying”.

27th November 2017

Thumbnail image for UK launch for Medicis Health’s Reconval creams

UK launch for Medicis Health’s Reconval creams

Specialty pharma Medicis Health has launched two new products in the UK approved for relief and protection against possible serious skin problems in patients receiving treatment for cancer and multiple sclerosis.

27th November 2017

Thumbnail image for Lirilumab/Opdivo combo shows ‘no clear evidence of benefit’

Lirilumab/Opdivo combo shows ‘no clear evidence of benefit’

Shares in Innate Pharma plunged near 50 percent on Thursday after it said that a combination of lirilumab and Bristol-Myers Squibb's PD-1 inhibitor Opdivo failed to provide clear evidence of benefit in patients with squamous cell carcinoma of the head and neck.

24th November 2017

Thumbnail image for Roche’s Erivedge no longer funded by the NHS

Roche’s Erivedge no longer funded by the NHS

Roche’s Erivedge will indeed no longer be funded on the National Health Service as a treatment for skin cancer after cost regulators issued final guidance ruling that it is not cost effective.

23rd November 2017

Thumbnail image for Health/industry groups react to Autumn Budget

Health/industry groups react to Autumn Budget

Chancellor Philip Hammond’s Autumn Budget has promised an extra £2.8 billion for NHS services over the next three years, though the amount falls well short of the £4 billion deemed by health leaders as necessary to retain the current quality of services.

23rd November 2017

Thumbnail image for EU approves post-chemo option for patients with ovarian cancer

EU approves post-chemo option for patients with ovarian cancer

European regulators have cleared Tesaro’s Zejula, offering a new option for the maintenance treatment of certain adults with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.

22nd November 2017

Previous  --   7 8 9 10 11 12 13 14 15 16   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download